Archives

Ampersand Biomedicines Presents Preclinical Data on AMP-220, a Gut-Targeted IL-22 AND-Body™ Therapeutic, at AAI 2026

B New data demonstrate the IL-22 AND-Body™ therapeutic, AMP-220, selectively targets gut tissue, conferring improved therapeutic efficacy and tolerability in vivo IND-enabling studies for AMP-220… Login to continue reading Login…

Read MoreAmpersand Biomedicines Presents Preclinical Data on AMP-220, a Gut-Targeted IL-22 AND-Body™ Therapeutic, at AAI 2026

5,000 Miles for a Cure: Human Powered Potential Announces “Second Wave” Row to Raise Funds to End Parkinson’s Disease

B HPP’s ‘Second Wave’ Team Kicks Off Training for Record-Setting Next Row SANFORD, Fla., April 20, 2026 /PRNewswire/ — During Parkinson’s Awareness Month, a team… Login to continue reading Login…

Read More5,000 Miles for a Cure: Human Powered Potential Announces “Second Wave” Row to Raise Funds to End Parkinson’s Disease

Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update

B STATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new… Login to continue reading Login…

Read MoreAcurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update